Washington Post Publisher Will Lewis Steps Down After Layoffs 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
MORRISVILLE, N.C., Oct. 27, 2017 -- Hampton Corley, Chief Business Officer of Clinipace Worldwide, a global full-service clinical research organization (CRO), has been appointed to the Board of Directors of the American Society of Nephrology’s Kidney Health Initiative (KHI). Corley will serve on the Board for a renewable three-year term from January 1, 2018, to December 31, 2020.
“I welcome this opportunity to support the efforts of the KHI,” said Corley. “Our company endorses the initiative’s mission of advancing scientific understanding of the kidney health and patient safety implications of new and existing medical products, and therapy development for kidney disease – an area of great unmet need.”
“Nephrology is a key therapeutic area for Clinipace going forward,” said Eric B. Grossman, MD, Vice President and Medical Director of Clinipace Worldwide. “We especially support the KHI’s efforts to create a collaborative environment in which sponsors, regulators, Principal Investigators and the greater nephrology community can interact to optimize evaluation of therapies.”
Clinipace will attend the KHI Open House on Friday, November 3, in New Orleans, during the ASN Kidney Week.
About Clinipace Worldwide
Clinipace Worldwide, a global full-service clinical research organization (CRO) serves the unique needs of venture-backed, mid-tier and strategic pharmaceutical, biotechnology and medical device firms, helping them advance drug candidates to deliver successful stakeholder and patient outcomes. The company leverages extensive therapeutic knowledge and clinical trial expertise to support life science firms in achieving some of their most important goals: executing regulatory strategies, optimizing clinical development timelines and completing high quality trials. Committed to delivering against timelines and milestone events, Clinipace has completed more than 1,500 clinical trials and 1,500 regulatory and statistical consulting projects and operates in North America, South America, Europe, and Asia. To learn more, visit www.clinipace.com.
Media Contact:
Sandra Parrish Woodlief
919-797-9480
